Subscribe to RSS
Download PDF
DOI: 10.1160/TH03-11-0680
Treatment with anticoagulants in cerebral events (TRACE)
Financial support: Our department has received funds from Aventis Pharma (formerly Rhone-Poulenc Rorer). All funds are administered and distributed through the departmental administration after a review process. None of the authors has received any funds personally.
Publication History
Received
08 November 2003
Accepted after revision
21 January 2004
Publication Date:
06 December 2017 (online)
Summary
90 patients with acute stroke and a concomitant cardiac embolism source or a symptomatic high-grade stenosis of an extraor intracranial vessel received in a mulitcenter, randomized, controlled study either Enoxaparin 1 mg/kg BW s.c. b.i.d. or i.v. heparin aPTT-adjusted daily for 8 +/−2 days as secondary prophylaxis. There were no significant differences between the two groups regarding cerebral and systemic embolic events, bleeding complications, length of hospital stay, number of diagnostic and therapeutic measures and outcome after three months. This suggests that Enoxaparin, which is easier to administer and monitor, is a safe drug in patients with acute cerebral events.
* J Treib designed the study. All authors collected data, did the analyses and contributed to the writing of the report.
-
References
- 1 Treib J, Grauer MT, Woessner R. et al. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2000; 26: 1598-1611.
- 2 Estol CJ, Swanson RA. Intravenous heparin for acute stroke: What can we learn from the megatrials?. Neurology 2000; 54: 1542-6.
- 3 Berge E, Abdelnoor M, Nakstad PH. et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205-10.
- 4 The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998; 279: 1265-72.
- 5 Diener HC, Ringelstein EB, von Kummer R. et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001; 32: 22-9.
- 6 Bath PMW, Lindenstrom E, Boysen G. et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-10.
- 7 Babaikain VL, Spencer M, Ackerstaff GA. et al. Basic identification criteria of Doppler microembolic signals. Stroke 1995; 26: 1123.